ACTICOR BIOTECH

Acticor Biotech plans to reposition itself in myocardial infarction treatment, with its share price rising 45% on the Paris Bourse. The company is conducting a Phase 2b study with the University of Birmingham to assess glenzocimab's efficacy and safety in reducing infarct size. A Phase 2 study is also being prepared, aiming to enroll 300 patients in cardiac intensive care units, with results expected in Q4 2026. Patient recruitment for the Phase 2 study could begin in Q1 2025, subject to financing. François Guillet has been appointed as CFO.

ACTICOR BIOTECH updates on LIBERATE (phase 2b) and GLORIA (phase 2) studies evaluating glenzocimab for myocardial infarction treatment, aiming for phase 3 registration by 2027.